Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 8.4%. This drawdown was discouraging since the S&P 500 held its ground.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.
With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?
